ALSEMPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of ALSEMPHARMA is 4.0% (moderate). The 2025 annual accounts show negative equity (-€66,946) and a net result of -€47,740. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 8% of 4,961 sector peers (NACE 47, financial year 2025). The company has been active since 1997 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
07-07
Gazette deed
Resignations: TWEE - DE NV (director) and DEVELTER Peter (director)Appointment: HUNTSOLEM BV (director) · Permanent representative: LEROUX Caroline8 facts ▸
- General meeting, 15-06-2025
- Director resignation, TWEE - DE NV (director)
- Director resignation, DEVELTER Peter (director)
- Director appointment, HUNTSOLEM BV (director)
- Permanent representative, LEROUX Caroline
- Board meeting, 15-06-2025
- Director resignation, TWEE - DE NV (managing director)
- Director appointment, HUNTSOLEM BV (managing director)
About the unread acts
Of the 6 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 5 have not been read yet: what they contain is neither established nor disproved here.